CLChuang Li

Chuang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chuang Li has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Zhou

    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    3 shared publications
  • Ruoyu Wang

    Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    3 shared publications
  • Songbai Chen

    Department of Radiology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    3 shared publications
  • Yunfeng Kou

    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    2 shared publications
  • Yuting Yuan

    Department of Intervention, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    2 shared publications
  • Zhe Wang

    Dalian Univ, Affiliated Zhongshan Hosp, Dept Med Oncol, Dalian, Peoples R China

    2 shared publications

Latest Publications

  • Open Access

    CalliSpheres® drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in patients with refractory liver metastases: a propensity score-matched multi-center study

    by Guang Sheng Zhao, Song Liu, Shun Hang Yin, Fang Xu, Jun Jie Qu, Fei Gao, Zhuo Feng, Chuang Li, Jun Zhou, Guang Ji Yu, et al.

  • Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications

    by Yi Zhang, Jiaxin Fan, Yuhan Ye, Chuang Li, Ming-Fei Lang

    Lung cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for more effective therapeutic strategies. Lung cancer stem cells (LCSCs) play critical roles in tumor initiation, metastasis, therapeutic resistance, and recurrence through dynamic interactions with the tumor microenvironment (TME), metabolic reprogramming, and immune evasion. Despite advances in targeted therapy and immunotherapy, conventional approaches remain insufficient for the complete elimination of LCSCs. Recent progress in nanotechnology has provided new opportunities for precision targeting of LCSCs by enhancing drug bioavailability, tumor selectivity, controlled release, and multifunctional therapeutic integration. In this review, we summarize current nanotechnology-enabled strategies targeting LCSCs, with particular emphasis on TME remodeling, metabolic regulation, and tumor immunity. Distinct from previous reviews that discuss cancer stem cells or nanomedicine separately, this review establishes an integrated framework linking LCSC niche regulation with nanotechnology-based precision therapeutics in lung cancer. We further highlight the therapeutic potential of multifunctional nanoplatforms, including nanocrystalline drugs, smart nanocarriers, and combinational nano-delivery systems, in modulating stemness-associated pathways, overcoming immune suppression, and disrupting metabolic adaptation. In addition, emerging strategies involving stimulus-responsive nanomaterials, ferroptosis induction, and engineered immunotherapeutic platforms are discussed. Finally, current challenges and future perspectives regarding tumor heterogeneity, nanocarrier biocompatibility, translational feasibility, and personalized therapeutic design are addressed. Collectively, this review provides a comprehensive perspective on nanotechnology-enabled precision targeting of LCSCs and offers insights into next-generation therapeutic strategies for lung cancer.

  • Open Access

    Analysis of short-term clinical efficacy and immune function changes of advanced non-small cell lung cancer after radiotherapy or chemotherapy under CT-guided 125I seed implantation

    by Songbai Chen, Yunfeng Kou, Yuting Yuan, Guangsheng Zhao, Jun Zhou, Ruoyu Wang, Zhe Wang, Chuang Li

    Objective: To evaluate the clinical efficacy, safety, and changes in the immune status of advanced non-small cell lung cancer (NSCLC) patients with disease progression after chemoradiotherapy treated with CT-guided 125 I radioactive seed implantation. Materials and methods: From January 2016 to June 2022, 34 NSCLC patients who progressed after radiotherapy and chemotherapy were studied retrospectively. There were 34 evaluable lesions, and 125 I seeds were implanted into the lesions under CT guidance. The study’s endpoints were as follows: short-term clinical efficacy, quality of life score, and adverse reaction status assessment, with patients being collected for immune status assessment. Results: The average postoperative follow-up period was 16.58 ± 7.41 months. The 1-year postoperative survival rate was 76.47% (26/34), the 2-year postoperative survival rate was 58.82% (20/34), and the median overall survival was 16 (6–24) months (95% CI: 13.7–18.3). The 1-year progression-free survival (PFS) rate after the operation was 61.76% (21/34), the 2-year PFS rate was 41.18% (14/34), and the median PFS was 12.5 (1–24) months (95% CI: 10.8–16.2). Postoperative pneumothorax occurred in 11.76% of patients, minor bleeding in 5.88%, and pneumonia in 2.94%, all of which improved after symptomatic treatment. Compared with the preoperative results, the percentages of CD3 + and CD4 + T lymphocytes in the treatment group increased 1, 2, 3, and 6 months after surgery; the percentage of NK cells increased 3 and 6 months after surgery. The positive immune factor levels of IL-2 and TNF-α were increased at 2, 3, and 6 months after surgery; γ-IFN levels were increased at 1, 2, 3, and 6 months after surgery; IL-4 levels were decreased at 3 and 6 months after surgery; and IL-10 levels were decreased at 6 months after surgery. TH17 (IL-17) levels decreased at 1, 2, 3, and 6 months after surgery. Conclusion: CT-guided 125 I particle therapy may be an effective treatment for NSCLC that has progressed following radiotherapy and chemotherapy. Local treatments improve patients’ quality of life and reduce tumor burden. CT-guided 125 I radioactive seed implantation may improve the immune status of patients with recurrent or progressive NSCLC after radiotherapy and chemotherapy and may enhance the antitumor immune response.


  • Experimental validation of the accuracy of robotic-assisted radioactive seed implantation for tumor treatment

    by Zhe Ji, Zhe Wang, Yuliang Jiang, Haitao Sun, Bin Qiu, Chuang Li, Bo Liu, Qianqian Li, Leifeng Zhang, Xiangzhi Bai, et al.

    An experimental validation of a robotic system for radioactive iodine-125 seed implantation (RISI) in tumor treatment was conducted using customized phantom models and animal models simulating liver and lung lesions. The robotic system, consisting of planning, navigation, and implantation modules, was employed to implant dummy radioactive seeds into the models. Fiducial markers were used for target localization. In phantom experiments across 40 cases, the mean errors between planned and actual seed positions were 0.98 ± 1.05 mm, 1.14 ± 0.62 mm, and 0.90 ± 1.05 mm in the x, y, and z directions, respectively. The x, y, and z directions correspond to the left–right, anterior–posterior, and superior-inferior anatomical planes. Silicone phantoms exhibiting significantly smaller x-axis errors compared to liver and lung phantoms (p < 0.05). Template assistance significantly reduced errors in all axes (p < 0.05). No significant dosimetric deviations were observed in parameters such as D90, V100, and V150 between plans and post-implant doses (p > 0.05). In animal experiments across 23 liver and lung cases, the mean implantation errors were 1.28 ± 0.77 mm, 1.66 ± 0.69 mm, and 1.86 ± 0.93 mm in the x, y, and z directions, slightly higher than in phantoms (p < 0.05), with no significant differences between liver and lung models. The dosimetric results closely matched planned values, confirming the accuracy of the robotic system for RISI, offering new possibilities in clinical tumor treatment.


  • Open Access

    Clinical efficacy of iodine-125 radioactive particle implantation with deep hyperthermia in malignant tumor treatment: A retrospective analysis

    by Yuting Yuan, Yunfeng Kou, Jian Yu, Shenghe Zhang, Songbai Chen, Ruoyu Wang, Zhe Wang, Jun Zhou, Chuang Li

    Purpose: In the current study, the clinical efficacy of iodine-125 ( 125 I) radioactive particle implantation with deep hyperthermia in malignant tumor treatment was retrospectively analyzed. Material and methods: Sixty patients with malignant tumors treated at Zhongshan Hospital affiliated...

  • Digital Subtraction Angiography and Magnetic Resonance Imaging-Based Staging of Circulatory Obstruction in the Femoral Head During Osteonecrosis of the Femoral Head Development

    by Benjie Wang, Lu Li, Yikai Wang, Zihua Wang, Chuang Li, Weimin Fu, Xing Qiu, Dewei Zhao

    Introduction Nontraumatic osteonecrosis of the femoral head (NONFH) is a common and difficult disease in orthopedics. Magnetic resonance imaging (MRI) assessment of NONFH and bone marrow edema was combined with digital subtraction angiography (DSA) to evaluate the circulatory status of NONFH in different Association Research Circulation Osseous stages. Based on the circulatory obstruction status (venous stasis, arterial ischemia, and arterial occlusion), appropriate perioperative management was adopted to achieve hip joint preservation and effectively delay the time for total hip arthroplasty in young patients. Methods From January 2013 to March 2019, 41 orthopedic patients were evaluated for medical imaging. Sixty-one ONFH cases were enrolled. The inclusion criteria include: (1) Clear diagnosis of osteonecrosis of the femoral head. (2) No history of infection in the affected hip, no history of hip surgery, and no congenital hip diseases. The patients enrolled in this study were 8 women and 33 men between the ages of 19 and 64 years (mean, 39.25 +/- 8.90 years). Preoperative X-ray, computed tomography, MRI, DSA, and histological data were taken. Results The combination of DSA and MRI can efficiently show blood supply changes in the femoral head of NONFH patients at different Association Research Circulation Osseous stages; and also can possibly reveal the causes and development of NONFH. Different stages of circulatory obstruction of the femoral head can be clearly distinguished and used to determine the required perioperative management, thus yielding successful surgical outcomes. Conclusions The existing classification systems do not fully reflect the progression of circulatory obstruction in ONFH. Each stage of NONFH development has its own characteristics circulatory obstruction. Early-stage NONFH displays characteristic venous stasis of the femoral head, whereas advanced stage NONFH is characterized by insufficient arterial blood supply to the femoral head. Corresponding NONFH treatment strategies should be considered based on their specific circulatory status. This work also provides guidance and recommendations for adopting corresponding femoral head preserving strategies for young patients in different NONFH circulatory status.


  • Open Access

    Therapeutic effect and tolerability of gelatin sponge particle-mediated chemoembolization for colorectal liver metastases: a retrospective study

    by Chuang Li, Yuewei Zhang, Jun Zhou, Guangsheng Zhao, Shunxiong Tang

    Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. The majority (approximately 60%) of patients with CRC will eventually develop liver metastases, which remain the most common cause of mortality in these patients. This study aimed to evaluate the therapeutic effect and tolerability of gelatin sponge particle (GSP)-mediated chemoembolization in the treatment of colorectal liver metastases after systemic chemotherapy failure. Methods: This was a single-center retrospective study of 15 patients with colorectal liver metastases, who underwent GSP-mediated chemoembolization with 50 mg of lobaplatin during the period December 2009 to December 2010 in the Department of Interventional Radiology, Affiliated Zhongshan Hospital of Dalian University. Clinical data were retrieved, and the therapeutic effect and tolerability of the treatment were evaluated. Results: All 15 patients with colorectal liver metastases completed the GSP-mediated chemoembolization. The therapeutic effect and tolerability were evaluated 3 months after the initial procedure. The tumor lesions in all patients showed various levels of necrosis and shrinkage. According to the Response Evaluation Criteria in Solid Tumors (RECIST), one patient achieved complete response (CR), eleven patients achieved partial response (PR), and three patients achieved stable disease (SD). The overall response rate (CR + PR) was 80%. Conclusions: GSP-mediated chemoembolization is well tolerated and has a good short-term response rate (80%) in the treatment of colorectal liver metastases after systemic chemotherapy failure. Collectively, further study of the long-term effect of GSP-mediated chemoembolization in colorectal liver metastasis in a large cohort is warranted.